Dermatophagoides farinae allergen epitopes (Der f)

Dermatophagoides farinae allergen epitopes are the specific molecular regions of proteins derived from the American house dust mite that are recognized by the human immune system, primarily through IgE antibodies and T-cell receptors. These allergens, which include major components like Der f 1 (a cysteine protease) and Der f 2 (a lipid-binding protein), are found in mite fecal pellets and body fragments and are a leading cause of indoor respiratory allergies worldwide (thermofisher.com, nih.gov). In sensitized individuals, exposure to these epitopes triggers a Type I hypersensitivity reaction, leading to conditions such as allergic asthma, rhinitis, and atopic dermatitis (wyndly.com, azallergy.com). In a therapeutic context, these allergen epitopes serve as the active components in allergen immunotherapy (AIT), where controlled exposure to standardized extracts or recombinant proteins aims to desensitize the patient (clinicaltrials.eu, fda.gov). The goal of such therapy is to induce immunological tolerance by promoting the development of regulatory T cells (Tregs) and increasing the production of "blocking" IgG4 antibodies, thereby reducing the Th2-driven inflammatory response (nih.gov). Drugs targeting these epitopes, such as sublingual tablets (e.g., Odactra) or subcutaneous injections, are widely used to provide long-term relief and modify the course of allergic disease (fda.gov).

Other names

American house dust mite allergensDer f allergensHouse dust mite allergen epitopesDermatophagoides farinae antigens

Allergen immunotherapy (AIT) induces immunological tolerance by shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile, increasing allergen-specific IgG4 and reducing IgE-mediated mast cell degranulation (nih.gov, clinicaltrials.eu).